Direct activation and anti-repression functions of GAL4-VP16 use distinct molecular mechanisms.
In order to determine whether the molecular mechanisms used for direct activation by GAL4-VP16 are the same as those used for anti-repression, we have employed monoclonal antibodies specific for the VP16 activation domain. In the absence of added repressors, GAL4-VP16 was able to stimulate transcription from a template containing GAL4-binding sites, and the antibodies raised against the VP16 activation domain failed to inhibit this direct activation. GAL4-VP16 also was able to prevent histone H1-mediated repression by a mechanism that was strongly dependent on the presence of specific GAL4-binding elements in the promoter. However, in contrast to the assays conducted in the absence of repressors, the antibodies were strong inhibitors of GAL4-VP16-activated transcription in the presence of histone H1. Thus the binding of the antibodies distinguished between the direct activation and anti-repression functions of GAL4-VP16, indicating that these functions operate through distinct molecular mechanisms. The anti-repression-specific mechanism that is inhibitable by the antibodies acted at an early stage of preinitiation complex formation. Deletions of individual subdomains of the VP16 activation domain demonstrated that there was not a discrete subdomain responsible for the anti-repression function of GAL4-VP16. Thus, the inhibitory effect of the antibodies appeared to be due to the location of the epitope within the activator protein rather than to some inherent biochemical property of that region of the protein that is required specifically for anti-repression. The inhibitory effect of the antibodies also ruled out the possibility that steric exclusion of repressor proteins from the promoter was the sole means of anti-repression by the transcriptional activator.
Lyons
J G
JG
Laboratoire de Génétique Moléculaire des Eucaryotes du CNRS, Unité 184 de Biologie Moléculaire et de Génie Génétique de l'INSERM, Faculté de Médecine, Strasbourg, France.
Chambon
P
P
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001483:Base Sequence; D001665:Binding Sites; D005656:Fungal Proteins / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D006657:Histones / Q000494:pharmacology; D008969:Molecular Sequence Data; D016296:Mutagenesis; D012097:Repressor Proteins / Q000037:antagonists & inhibitors*; D015534:Trans-Activators / Q000737:chemistry / Q000235:genetics / Q000494:pharmacology*; D014158:Transcription, Genetic / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D005656:Fungal Proteins; C070633:Gal-VP16; D006657:Histones; D012097:Repressor Proteins; D015534:Trans-Activators